January 05, 2026 a 07:43 pm
VRTX: Fundamental Ratio Analysis - Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a strong player in the biotechnology industry, with a focused approach towards cystic fibrosis therapies among other promising pipelines. Despite facing competition, VRTX continues to maintain growth with comprehensive R&D strategies and collaborations.
Fundamental Rating
Vertex Pharmaceuticals demonstrates strong fundamentals with a high rating, indicating robust financial health and growth potential.
| Category | Score | Visual |
|---|---|---|
| Overall | 4 | |
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 3 | |
| Price to Earnings | 2 | |
| Price to Book | 2 |
Historical Rating
Comparative analysis of past and current fundamentals indicates stability and consistent performance.
| Date | Overall | Discounted Cash Flow | ROE | ROA | Debt to Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-01-05 | 4 | 5 | 5 | 5 | 3 | 2 | 2 |
| Previous | 0 | 5 | 5 | 5 | 3 | 2 | 2 |
Analyst Price Targets
Analysts project a positive outlook with a significant upward potential in price targets, reflecting confidence in VRTX's future performance.
| High | Low | Median | Consensus |
|---|---|---|---|
| $564 | $414 | $487.5 | $489.9 |
Analyst Sentiment
Analyst sentiment is largely optimistic, with a dominant 'Buy' recommendation underscoring confidence in VRTX's market position.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 41 | |
| Hold | 13 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Vertex Pharmaceuticals Incorporated presents a strong investment case backed by a comprehensive pipeline and solid financial metrics. The company's innovation and strategic partnerships positively impact its market standing. While external market factors pose risks, the existing analyst confidence and robust scores suggest sustained growth potential.